Durvalumab (MEDI 4736) in combination with extended neoadjuvant regimens in rectal cancer : a study protocol of a randomised phase II trial (PRIME-RT)
- Hanna, Catherine R.
- O’Cathail, Sean M.
- Graham, Janet S.
- Saunders, Mark
- Samuel, Leslie
- Harrison, Mark
- Devlin, Lynsey
- Edwards, Joanne
- Gaya, Daniel R.
- Kelly, Caroline A.
- Lewsley, Liz-Anne
- Maka, Noori
- Morrison, Paula
- Dinnett, Louise
- Dillon, Susan
- Gourlay, Jacqueline
- Platt, Jonathan J.
- Thomson, Fiona
- Adams, Richard A.
- Roxburgh, Campbell S. D.
Publication date
August 2021
DOI Publisher
Springer Science and Business Media LLC Journal
Radiation Oncology Language
EnglishAbstract
Acknowledgements We are grateful to Mr George Davidson and Ms Monica Jeffers for their input with writing the PRIME-RT protocol and patient information sheet. This study is co-sponsored by the University of Glasgow and NHS Greater Glasgow and Clyde. Funding PRIME-RT is funded by Astrazeneca and receives core funding from CRUK Clinical Trials Unit Glasgow for the purposes of trial set-up and data collection. The trial is co-sponsored by the University Of Glasgow and NHS Greater Glasgow and Clyde.Peer reviewedPublisher PD
Add to ORKG